Biomarker Guidance To Encompass More Than Biomarkers, FDA Says
The draft guidance for biomarker qualification FDA is developing has taken a turn mid-stream and will focus on an array of drug development tools
You may also be interested in...
Changes in how efficacy of ulcerative colitis drugs are measured are coming, but FDA GREAT2 workshop focused on criteria to use in the interim. An academic/industry consortium plans to submit proposed patient-reported outcome questionnaires for UC and Crohn’s disease to the agency Dec. 20.
Updated draft white paper on expanding use of accelerated approval suggests FDA approve the use of biomarkers as surrogate endpoints in the pre-IND stage, which could enhance sponsors’ abilities to raise funds for trials and manufacturing.
FDA’s midstream decision to expand a biomarker qualification draft guidance to include patient-reported outcome tools has perplexed pharma stakeholders, which seem to think the agency would have been better off leaving well enough, and PROs, alone.